Literature DB >> 30299113

Zygomatic Implants for the Management of Severe Alveolar Atrophy in the Partial or Completely Edentulous Maxilla.

Paul S Petrungaro1, Gregori M Kurtzman2, Santiago Gonzales3, Carlos Villegas4.   

Abstract

Treatment of severely resorbed partially or completely edentulous maxillae can include the utilization of the zygomatic process for immediate implant fixation and stabilization with immediate function. This approach may alleviate the need for significant grafting to enable implant placement in the posterior maxilla and allow implants to be placed into denser, more stable bone. Zygomatic implants, which have been used clinically for the past 20 years in the treatment of the severely resorbed maxilla, allow implant placement to support fixed prosthetics. Their usage can potentially shorten treatment time and reduce costs, as the need to wait for osseous graft maturation is eliminated. Guided surgical approaches are being utilized to maximize placement of the prosthetic platform of these implants.

Entities:  

Mesh:

Year:  2018        PMID: 30299113

Source DB:  PubMed          Journal:  Compend Contin Educ Dent        ISSN: 1548-8578


  3 in total

Review 1.  Quality assessment of systematic reviews regarding the effectiveness of zygomatic implants: an overview of systematic reviews.

Authors:  P-H Sales; M-V Gomes; O-B Oliveira-Neto; F-J de Lima; J-C Leão
Journal:  Med Oral Patol Oral Cir Bucal       Date:  2020-07-01

Review 2.  Zygomatic implants placed in atrophic maxilla: an overview of current systematic reviews and meta-analysis.

Authors:  Shaqayeq Ramezanzade; Julian Yates; Frank J Tuminelli; Seied Omid Keyhan; Parisa Yousefi; Jose Lopez-Lopez
Journal:  Maxillofac Plast Reconstr Surg       Date:  2021-01-06

3.  Navigated Antral Bone Expansion (NABE): a prospective study on 35 patients with 4 months of follow-up post implant loading.

Authors:  Luigi V Stefanelli; Nicola Pranno; Francesca De Angelis; Silvia La Rosa; Antonella Polimeni; Stefano Di Carlo
Journal:  BMC Oral Health       Date:  2020-10-07       Impact factor: 2.757

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.